Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 12/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 12/20 | 0.54 |
| ▸ | PDE4A | P27815 | 6/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.54 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440910 | 0.84 | PDE3B (0.62) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7271444 | 0.82 | PDE3B (0.52) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL8199834 | 0.82 | PDE3B (0.52) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL6866194 | 0.82 | PDE3B (0.53) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL13864400 | 0.81 | PDE3B (0.55) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7343569 | 0.77 | PDE3B (0.48) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7323199 | 0.77 | FBP1 (0.52) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL3440851 | 0.76 | MAPT (0.64) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7295733 | 0.73 | PDE3B (0.52) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7432080 | 0.73 | PDE3B (0.52) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341539-B1 | ANTI-INFLAMMATORY AGENTS | ORION CORP (FI) | 2005-05-04 | — | — | EP | disclosed |
| US-6878702-B2 | Anti-inflammatory agents | ORION CORPORATION (FI) | 2005-04-12 | — | — | US | disclosed |
| US-20040029870-A1 | Anti-inflammatory agents | ORION CORPORATION (FI) | 2004-02-12 | — | — | US | disclosed |
| EP-1341539-A1 | ANTI-INFLAMMATORY AGENTS | ORION CORPORATION (FI) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002040025-A1 | ANTI-INFLAMMATORY AGENTS | ORION CORPORATION (FI) | 2002-05-23 | — | — | WO | disclosed |
| US-5246928-A | Cardiovascular disorders | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-09-21 | — | — | US | disclosed |
| US-5185332-A | Treating congestive heart failure | ORION-YHTYMA OY (FI) | 1993-02-09 | — | — | US | disclosed |
| US-5066653-A | Cardiovascular disorders; bronchodilators; phosphodiesterase inhibitors | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-11-19 | — | — | US | disclosed |
| US-4906628-A | N-phenylpyridone type III phosphodiesterases | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-06 | — | — | US | disclosed |
| EP-0220044-A2 | 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029870-A1 | Anti-inflammatory agents | AIFM1, PTGS1, CASP1 | PDE3B 1050/4885PDE3A 1298/4885PDE4A 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.